Mirion Technologies (NYSE:MIR) reported Q4 CY2025 revenue of $277.4 million, up 9.1% year-on-year, but missed revenue and non-GAAP EPS estimates. Non-GAAP profit of $0.15 per share was 7.8% below consensus; the stock fell 6.7% to $21.86 in after-hours trading.
Supporting context: The company serves radiation safety needs in over 130 countries and is used in 80% of cancer centers globally. Revenue grew 11.8% CAGR over five years but 7.5% annualized in the past two. Analysts project 22.6% revenue growth and 26.4% EPS expansion over the next 12 months. Operating margin expanded 8.9 percentage points over five years but dipped 2.3 points in Q4, down from 9.2% to 6.9%. Full-year EPS growth of 18.8% over two years contrasts with a 3% annual decline over three years. The miss reflects higher expenses outpacing sales, with a Q4 adjusted EPS of $0.15 missing estimates.
Supporting context: The company serves radiation safety needs in over 130 countries and is used in 80% of cancer centers globally. Revenue grew 11.8% CAGR over five years but 7.5% annualized in the past two. Analysts project 22.6% revenue growth and 26.4% EPS expansion over the next 12 months. Operating margin expanded 8.9 percentage points over five years but dipped 2.3 points in Q4, down from 9.2% to 6.9%. Full-year EPS growth of 18.8% over two years contrasts with a 3% annual decline over three years. The miss reflects higher expenses outpacing sales, with a Q4 adjusted EPS of $0.15 missing estimates.